- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
John Orwin, Genentech
S
ONE TO WATCH:
John Orwin, SVP, Sales and Marketing, BioOncology, Genentech
Orwin learned the landscape of onoclogy while working as senior director of oncology marketing at Alza, and then eventually as the franchise VP at J&J's Tibotec division. In 2005, he headed out to Cali to join Genentech, and was promoted the same year to head sales and marketing of its BioOncology division. And it's a good thing: Orwin was part of the commercial genius that built such heavyweights as Avastin, Herceptin, and Rituxan.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
